The challenge of approving add-on therapies for patients with metastatic cancer

Molecular medicine in lung cancer

Current and future immune approaches in precision medicine

Synthetic lethality as a basis to select drug combinations

Novel models to personalise cancer therapeutics

Low dose exemestane usage in breast cancer

BRCA1 and BRCA2 genes and hereditary breast cancers

Delayed infection exposure as a trigger for childhood ALL

Disruption of BAFF-BCR crosstalk in CLL

Phase Ib/II study of nivolumab in combination with azacytidine in patients with relapsed AML

ZUMA1 trial of CD19 CAR T cells for aggressive NHL

Diverse T lymphocyte population fights leukaemia more effectively